# KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study

> **NCT07462559** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Helsinki University Central Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Drug Drug Interaction

## Interventions

- **DRUG:** Ketamine 10 mg/ml oral solution, UK special
- **DRUG:** Cobisistat Tybost 150 mg
- **DRUG:** Cannabidiol Epidyolex 100 mg/ml

## Key facts

- **NCT ID:** NCT07462559
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07462559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07462559, "KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07462559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*